These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9723518)

  • 1. Flow cytometry detection of intracytoplasmic cytokines after Neoral or sirolimus intake is an informative tool for monitoring in vivo immunosuppressive efficacy in renal transplant recipients.
    Tkaczuk J; Rostaing L; Puyoo O; Peres C; Abbal M; Durand D; Ohayon E
    Transplant Proc; 1998 Aug; 30(5):2400-1. PubMed ID: 9723518
    [No Abstract]   [Full Text] [Related]  

  • 2. FK506 and CsA differ in their effect on intracellular cytokine expression following kidney transplantation.
    Zamauskaite A; Cohen S; Sweny P; Madrigal A; Varghese Z; McLean A; Powis SH
    Transplant Proc; 2001; 33(1-2):1046-7. PubMed ID: 11267184
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model.
    Granger DK; Cromwell JW; Canafax DM; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):984. PubMed ID: 8623488
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytokine analysis to predict immunosuppression.
    Barten MJ; Rahmel A; Bocsi J; Boldt A; Garbade J; Dhein S; Mohr FW; Gummert JF
    Cytometry A; 2006 Mar; 69(3):155-7. PubMed ID: 16479614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of primate TH2 lymphokines to suppress TH1 cells.
    Smit JA; Stark JH; Myburgh JA
    Transplant Proc; 1996 Apr; 28(2):665-6. PubMed ID: 8623334
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of therapeutic drug monitoring of rapamycin.
    Kahan BD; Napoli KL
    Transplant Proc; 1998 Aug; 30(5):2189-91. PubMed ID: 9723436
    [No Abstract]   [Full Text] [Related]  

  • 7. Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation.
    Kahan BD
    Transplant Proc; 1995 Feb; 27(1):33-6. PubMed ID: 7879019
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
    Libetta C; Sepe V; Zucchi M; Portalupi V; Meloni F; Rampino T; Dal Canton A
    Kidney Int; 2007 Jul; 72(1):114-20. PubMed ID: 17410097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus: a new agent for clinical renal transplantation.
    Kahan BD
    Transplant Proc; 1997; 29(1-2):48-50. PubMed ID: 9123092
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapamycin in a porcine renal transplant model.
    Almond PS; Moss A; Nakhleh R; Melin M; Chen S; Salazar A; Shirabe K; Matas A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):716. PubMed ID: 8438452
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
    Brattström C; Tydén G; Säwe J; Herlenius G; Claesson K; Groth CG
    Transplant Proc; 1996 Apr; 28(2):985-6. PubMed ID: 8623489
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclosporine A is associated with a shift of the Th1/Th2 balance in liver transplant patients.
    van den Berg AP; Twilhaar WN; Corver K; Geerts AB; Mesander G; Klompmaker IJ; Slooff MJ; The TH; de Leij LH
    Transplant Proc; 1998 Aug; 30(5):2378-9. PubMed ID: 9723510
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival.
    Stepkowski SM; Kahan BD
    Transplant Proc; 1991 Dec; 23(6):3262-4. PubMed ID: 1750091
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunological evaluation of combination therapy with tacrolimus and sirolimus on long-term allograft survival in nonhuman primates.
    Ma A; Qi S; Xu D; Daloze P; Chen H
    Transplant Proc; 2005; 37(1):150-4. PubMed ID: 15808578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation.
    Kahan BD; Murgia MG; Slaton J; Napoli K
    Ther Drug Monit; 1995 Dec; 17(6):672-5. PubMed ID: 8588239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
    Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
    Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
    [No Abstract]   [Full Text] [Related]  

  • 17. Triple combination of cyclosporine, brequinar, and rapamycin prolongs kidney allograft survival in the mongrel dog.
    Ferraresso M; Knight R; Tu Y; Stepkowski SM; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3028. PubMed ID: 7940953
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting.
    Wang H; Hosiawa KA; Min W; Yang J; Zhang X; Garcia B; Ichim TE; Zhou D; Lian D; Kelvin DJ; Zhong R
    J Immunol; 2003 Oct; 171(7):3823-36. PubMed ID: 14500684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of blood transfusion and immunosuppression to the Th1/Th2 paradigm.
    Frede SE; Valente J; Alexander JW; Babcock GF
    Transplant Proc; 1997; 29(1-2):1153-4. PubMed ID: 9123246
    [No Abstract]   [Full Text] [Related]  

  • 20. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
    Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
    Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.